CAJ | 학술논문

目的观察缓释型促性腺激素释放激素类似物(GnRHa)治疗后的特发性中枢性性早熟(ICPP)男孩的成年身高.方法 20例ICPP男孩接受GnRHa治疗(20.0±6.1)个月,治疗开始时的年龄和骨龄分别为(11.4±1.0)和(13.0±0.4)岁,当年龄和骨龄达(13.2±1.1)和(13.7±0.6)岁时停止治疗,治疗结束后经随诊(3.3±1.5)年,均已达接近成年身高(FAH).比较预测成年身高(PAH)、FAH和遗传靶身高(THt),探讨GnRHa治疗ICPP男孩对于改善成年身高的远期疗效.结果成年身高均达遗传靶身高范围,FAH与THt的差异无统计学意义[(169.8±5.8对167.8±4.6)cm,P＞0.05].按骨龄身高SDS预测成年身高(生长曲线法),GnRHa治疗后的PAH较治疗前显著改善[(169.0±5.0对166.2±4.2)cm,P＜0.01]；治疗结束时的PAH、FAH和THt差异无统计学意义(P＞0.05)；身高净获为(3.62±3.57)cm;剩余生长能力为(11.82±3.99)cm.结论 GnRHa能改善ICPP男孩的成年身高.
목적 관찰완석형촉성선격소석방격소유사물(GnRHa)치료후적특발성중추성성조숙(ICPP)남해적성년신고.방법 20례ICPP남해접수GnRHa치료(20.0±6.1)개월,치료개시시적년령화골령분별위(11.4±1.0)화(13.0±0.4)세,당년령화골령체(13.2±1.1)화(13.7±0.6)세시정지치료,치료결속후경수진(3.3±1.5)년,균이체접근성년신고(FAH).비교예측성년신고(PAH)、FAH화유전파신고(THt),탐토GnRHa치료ICPP남해대우개선성년신고적원기료효.결과 성년신고균체유전파신고범위,FAH여THt적차이무통계학의의[(169.8±5.8대167.8±4.6)cm,P＞0.05].안골령신고SDS예측성년신고(생장곡선법),GnRHa치료후적PAH교치료전현저개선[(169.0±5.0대166.2±4.2)cm,P＜0.01]；치료결속시적PAH、FAH화THt차이무통계학의의(P＞0.05)；신고정획위(3.62±3.57)cm;잉여생장능력위(11.82±3.99)cm.결론 GnRHa능개선ICPP남해적성년신고.
Objective To observe the final adult height of 20 boys with idiopathic central precocious puberty (ICPP) treated with slow-releasing gonadotropin-releasing hormone analogue(GnRHa).Methods Twenty boys with ICPP were treated with GnRHa for( 20.0 ± 6.1 ) months.At the beginning of therapy,mean chronological age and bone age was( 11.4 ± 1.0 ) years and ( 13.0 ± 0.4 ) years,respectively,GnRHa was discontinued when the boys reached the chronological age and bone age of( 13.2 ± 1.1 ) years and ( 13.7 ± 0.6 ) years,respectively.After the end of treatment,all the boys had been followed up for( 3.3 ± 1.5 ) years and had achieved adult height.Comparisons were made among their predicted adult height ( PAH ),final adult height ( FAH ),and target height ( THt ).The long-term outcome of final adult height in boys with ICPP was investigated after GnRHa treatment.Results All the boys reached target height range.Final height was similar to the target height [ ( 169.8 ± 5.8 vs 167.8 ± 4.6 ) cm,P＞0.05 ].The height gain,defined as the difference between predicted adult height at the start of treatment using the height SDS for bone age and actual adult height was( 3.62 ± 3.57 ) cm with the residual growth capacity of ( 11.82 ±3.99)cm,PAH significantly improved after GnRHa treatment compared with before treatment [ ( 169.0 ± 5.0 vs166.2 ± 4.2 ) cm,P＜0.01 ].There were no differences among PAH,FAH,and THt.Conclusion GnRHa treatment improves final height within the range of target height in boys with central precocious puberty.